The National Institutes of Health (NIH) Clinical Center, Department of Transfusion Medicine, Infectious Diseases Section, intends to award a fixed-price purchase order on a sole-source basis to Agilent Technologies for the acquisition of an Agilent SureScan Microarray Scanner. This scanner, including all necessary hardware, software, and installation components, is required to support ongoing clinical research and development of diagnostic assays for hepatitis viruses and other transfusion-transmissible pathogens. The sole-source justification is based on proprietary compatibility with existing Agilent microarray platforms and software, the need for data continuity and integrity with previously generated datasets, unique technical capabilities not equivalently available in alternative systems, and seamless workflow integration within the laboratory. This acquisition will be conducted using simplified acquisition procedures under FAR Part 13. Interested parties who believe they can provide the required scanner and meet the technical requirements may submit their capabilities and interest to Kristin Nagashima via email by May 5, 2026, at 11:00 AM EST. The government reserves the discretion not to compete the requirement based on responses to this notice.
The bid notice does not specify a delivery deadline for the scanner.
The bid notice does not specify the payment terms.
The bid notice does not specify the warranty terms.
The bid notice states that the award will be on a firm fixed price sole source award basis.
The bid notice states that the Agilent SureScan Microarray Scanner is uniquely qualified due to proprietary compatibility, data continuity and integrity, unique technical capabilities, and workflow integration.
The bid notice does not specify any penalties.
The bid notice does not mention any requirement for a site visit.
The bid notice does not mention any requirement for sample submission.
The bid notice states that comments to this announcement may be submitted prior to the closing date specified in this announcement, which is May 5, 2026.
The bid notice does not specify the estimated total value of the acquisition.